Cullgen Stock

Cullgen, founded in 2018, is a biopharmaceutical company that develops new chemical entities (NCEs) designed to treat diseases that lack effective therapeutic approaches. Using its proprietary uSMITE™ platform, the company expands on the drug design paradigm aiming to target proteins that are typically resistant to treatments for selective destruction. Cullgen has produced several highly potent, selective, and bioavailable targeted protein degrader compounds. Cullgen is headquartered in San Diego, California.